Search Results

Regeneron, Akouos and Mass Eye and Ear are testing therapies that can reverse genetic protein deficiency to restore hearing, with promising early results.

REGENXBIO Inc. announced it will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk score can accurately predict the benefit of adding androgen deprivation therapy to radiation therapy in men with localized prostate cancer.

Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could address the damage underlying alpha-1 antitrypsin deficiency and make today’s treatments a thing of the past.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024.

The plethora of genes involved in obesity presents an intriguing opportunity for both gene silencing and ex vivo gene therapy approaches.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30.

Passage Bio, Inc. today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.